Overview
Compare with IP STRATEGY HOLDINGS, INC., EQUATOR Beverage Co or BUDA JUICE, INC., or pick any stock.
- TickerSRXH on NYSE1
- IndustryBeverages1
- HeadquartersNorth Palm Beach, Florida1
- Incorporated inDE3
- Business address801 Us Highway 1, North Palm Beach, Fl 334083
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation
See how the biggest companies compare on our leaderboards
Better Choice Company, Inc. (“Better Choice” or “BTTR”), the pet health and wellness business.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
23.4%Gross margin2
-174.6%Operating margin2
-688.8%Net margin2
-81.3%Revenue growth, 20252
-11058.0%Return on equity2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 84% of the revenue SRX Global Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2025 |
|---|---|
| United States | $5.5M |
| Taiwan | $833.0K |
| Other | $196.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue27¢$5.0M
- Selling, general and admin70¢$12.9M
- Interest3¢$628.0K
Out of $6.5M in revenue.2 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-09-30 | 2024-09-30 |
|---|---|---|
| Net sales | $6.5M | |
| Cost of goods sold | $5.0M | |
| Gross profit | $1.5M | |
| Selling, general and administrative | $12.9M | |
| Total operating expenses | $12.9M | |
| Loss from continuing operations | -$11.4M | |
| Interest expense | -$628.0K | |
| Loss on extinguishment of debt | -$716.0K | |
| Bargain purchase gain | $4.1M | |
| Total other income | $2.8M | |
| Net loss before income taxes | -$8.6M | |
| Net loss from continuing operations | -$8.6M | |
| Loss from discontinued operations | -$36.4M | -$43.1M |
| Total loss | -$45.0M | -$43.1M |
| Reclassification of AOCI related to discontinued operations | -$2.4M | |
| Foreign currency translation related to discontinued operations | $13.6M | |
| Total comprehensive loss | -$47.4M | -$29.4M |
| Weighted average number of shares outstanding, basic | 21.1M shares | 22.1M shares |
| Weighted average number of shares outstanding, diluted | 21.1M shares | 22.1M shares |
| Loss per share, basic | -$2.13 | -$1.95 |
| Loss per share, diluted | -$2.13 | -$1.95 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Cash and cash equivalents | $1.3M | $106.0K | |
| Accounts receivable, net | $3.9M | $9.3M | |
| Inventories, net | $2.1M | $3.4M | |
| Prepaid expenses and other current assets | $794.0K | $496.0K | |
| Current portion of lease receivable | $21.0K | ||
| Total Current Assets | $8.1M | $13.6M | |
| Fixed assets, net | $88.0K | $6.0M | |
| Right-of-use assets, operating leases | $20.0K | $6.5M | |
| Lease receivable, long-term | $456.0K | ||
| Intangible assets | $7.0M | ||
| Deferred tax assets | $150.0K | ||
| Other assets | $168.0K | ||
| Total Assets | $8.4M | $33.8M | |
| Accounts payable | $2.1M | $39.8M | |
| Accrued liabilities | $1.4M | $1.9M | |
| Current portion of long-term borrowings | $31.6M | ||
| Convertible debt, short-term | $2.2M | ||
| Operating lease liability, short-term | $21.0K | $1.5M | |
| Income tax payable | $300.0K | ||
| Deferred revenue | $29.0K | ||
| Short-term borrowings | $3.7M | ||
| Total Current Liabilities | $3.5M | $81.3M | |
| Long-term borrowings | $696.0K | ||
| Operating lease liability, long-term | $5.6M | ||
| Convertible debt, long-term | $4.5M | ||
| Deferred tax liability | $1.3M | ||
| Total Non-current Liabilities | $4.5M | $7.6M | |
| Total Liabilities | $8.0M | $88.9M | |
| Common Stock, $0.001 par value, 200,000,000 shares authorized, 24,915,740 & 22,495,955 shares issued and outstanding as of September 30, 2025 and 2024, respectively | $31.0K | $22.0K | |
| Additional paid-in capital | $23.3M | $12.5M | |
| Accumulated deficit | -$22.9M | -$70.0M | |
| Accumulated other comprehensive income | $2.4M | ||
| Total Stockholders Equity | $407.0K | -$55.1M | -$33.8M |
| Total Liabilities and Stockholders Equity | $8.4M | $33.8M | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares issued | 24.9M shares | 22.5M shares | |
| Common stock, shares outstanding | 24.9M shares | 22.5M shares |
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Cash and cash equivalents | $1.3M | $106.0K | |
| Accounts receivable, net | $3.9M | $9.3M | |
| Inventories, net | $2.1M | $3.4M | |
| Prepaid expenses and other current assets | $794.0K | $496.0K | |
| Current portion of lease receivable | $21.0K | ||
| Total Current Assets | $8.1M | $13.6M | |
| Fixed assets, net | $88.0K | $6.0M | |
| Right-of-use assets, operating leases | $20.0K | $6.5M | |
| Lease receivable, long-term | $456.0K | ||
| Intangible assets | $7.0M | ||
| Deferred tax assets | $150.0K | ||
| Other assets | $168.0K | ||
| Total Assets | $8.4M | $33.8M | |
| Accounts payable | $2.1M | $39.8M | |
| Accrued liabilities | $1.4M | $1.9M | |
| Current portion of long-term borrowings | $31.6M | ||
| Convertible debt, short-term | $2.2M | ||
| Operating lease liability, short-term | $21.0K | $1.5M | |
| Income tax payable | $300.0K | ||
| Deferred revenue | $29.0K | ||
| Short-term borrowings | $3.7M | ||
| Total Current Liabilities | $3.5M | $81.3M | |
| Long-term borrowings | $696.0K | ||
| Operating lease liability, long-term | $5.6M | ||
| Convertible debt, long-term | $4.5M | ||
| Deferred tax liability | $1.3M | ||
| Total Non-current Liabilities | $4.5M | $7.6M | |
| Total Liabilities | $8.0M | $88.9M | |
| Common Stock, $0.001 par value, 200,000,000 shares authorized, 24,915,740 & 22,495,955 shares issued and outstanding as of September 30, 2025 and 2024, respectively | $31.0K | $22.0K | |
| Additional paid-in capital | $23.3M | $12.5M | |
| Accumulated deficit | -$22.9M | -$70.0M | |
| Accumulated other comprehensive income | $2.4M | ||
| Total Stockholders Equity | $407.0K | -$55.1M | -$33.8M |
| Total Liabilities and Stockholders Equity | $8.4M | $33.8M | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares issued | 24.9M shares | 22.5M shares | |
| Common stock, shares outstanding | 24.9M shares | 22.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-09-30 | 2024-09-30 |
|---|---|---|
| Net loss | -$8.6M | -$43.1M |
| Income tax payable | -$170.0K | |
| Depreciation and amortization | $31.0K | $4.4M |
| Interest expense on lease liability | $464.0K | |
| Impairment of goodwill | $19.7M | |
| Impairment of intangibles | $1.6M | |
| Deferred tax expense | -$951.0K | |
| Share-based compensation | $3.2M | $3.7M |
| Bargain purchase gain | -$4.1M | |
| Debt discount amortization | $287.0K | |
| Loss on settlement of accounts payable | $716.0K | |
| Loss on sale of cryptocurrency assets | $35.0K | |
| Accounts receivable | $5.4M | -$409.0K |
| Inventories | $496.0K | $2.6M |
| Prepaid expenses and other assets | -$829.0K | $414.0K |
| Accounts payable | -$6.0M | $10.4M |
| Accrued and other liabilities | $1.3M | $9.0K |
| Cash Used in Operating Activities | -$8.1M | -$1.5M |
| Capital expenditures, net of disposals | $1.2M | |
| Purchase of cryptocurrency | -$2.1M | |
| Proceeds from sale of cryptocurrency | $2.0M | |
| Cash acquired in business combination | $5.9M | |
| Cash paid for acquisitions, net of assets acquired | -$2.3M | |
| Cash Provided by (Used in) Investing Activities | $5.9M | -$1.1M |
| Proceeds from long-term borrowings | $4.2M | |
| Repayment of long-term borrowings | -$3.4M | |
| Payment of principal portion of lease liabilities | -$2.7M | |
| Proceeds from share issuance | $919.0K | |
| Proceeds from short-term borrowings | $2.6M | |
| Increase in balance due to related parties | -$662.0K | |
| Proceeds from Wintrust facility | $859.0K | |
| Payments on Wintrust facility | -$1.7M | |
| Proceeds from short-term borrowings | $800.0K | |
| Repayment on short-term borrowings | -$800.0K | |
| Proceeds from issuance of convertible debt | $6.1M | |
| Repayment of convertible debt | -$1.7M | |
| Cash paid for financing costs | -$154.0K | |
| Proceeds from PIPE | $8.8M | |
| Payments for share repurchase | -$137.0K | |
| Cash Provided by Financing Activities | $12.2M | $932.0K |
| Net cash provided by (used in) continuing operations | $9.9M | -$1.6M |
| Net cash used in discontinued operations | -$8.5M | |
| Net increase (decrease) in cash | $1.4M | -$1.6M |
| Effect of foreign currency translation adjustments | -$207.0K | -$341.0K |
| Cash paid for interest during the period | -$329.0K | -$2.7M |
No quarter-by-quarter statement was filed.
Corporate structure
SRX Global Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of SRX Global Inc.
- Les Filles, LLC Filed SCHEDULE 13G/A on SRX Global Inc., latest Jul 8, 2026 (2 filings since Jun 25, 2026)
- Kevin Egan Filed SCHEDULE 13G on SRX Global Inc., latest Feb 12, 2026
- Altium Capital Management LLC Filed SCHEDULE 13G/A on SRX Global Inc., latest May 15, 2025 (4 filings since Aug 9, 2024)
- HEP Partners LLC Filed SC 13G/A on SRX Global Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2022)
- Edward James Brown Jr. Filed SC 13G/A on SRX Global Inc., latest Feb 14, 2023 (2 filings since Feb 28, 2022)
- John M. Word Iii. Filed SC 13G/A on SRX Global Inc., latest Feb 14, 2023 (2 filings since Feb 11, 2022)
- Brandywine Global Investment Management, LLC Filed SC 13G/A on SRX Global Inc., latest Feb 13, 2023 (2 filings since Feb 10, 2022)
- Cavalry Fund I LP Filed SC 13G/A on SRX Global Inc., latest Feb 13, 2023 (2 filings since Feb 4, 2022)
- Must Asset Management Inc. Filed SC 13G/A on SRX Global Inc., latest Feb 7, 2023 (3 filings since Nov 4, 2021)
- SRX Global Inc. North Palm Beach, Florida
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What SRX Global Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $540.0K2 Sep 30, 2025 | $11.2M2 Sep 30, 2024 | −95.2% |
| Accumulated depreciation | $452.0K2 Sep 30, 2025 | $5.2M2 Sep 30, 2024 | −91.3% |
| Property and equipment, net | $88.0K2 Sep 30, 2025 | $6.0M2 Sep 30, 2024 | −98.5% |
| Operating-lease assets (leased space) | $20.0K2 Sep 30, 2025 | $6.5M2 Sep 30, 2024 | −99.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $1.3M2 Sep 30, 2025 | $106.0K2 Sep 30, 2024 | +1134.9% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $405.0K10 Dec 31, 2024 | $18.3M2 Sep 30, 2023 | −97.8% |
| Intangible assets, net (excluding goodwill) | $7.0M2 Sep 30, 2024 | ||
| Finite-lived intangibles, gross | $12.0M2 Sep 30, 2024 | $14.7M9 Dec 31, 2022 | −18.1% |
| Accumulated amortization | -$3.5M2 Sep 30, 2024 | -$4.6M9 Dec 31, 2022 | +25.5% |
| Finite-lived intangibles, net | $7.0M2 Sep 30, 2024 | $10.1M9 Dec 31, 2022 | −30.4% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $2.1M2 Sep 30, 2025 | $3.4M2 Sep 30, 2024 | −38.3% |
| Supplies | $542.0K2 Sep 30, 2025 | $1.1M10 Dec 31, 2023 | −51.3% |
Properties, in its own words
Our principal place of business is located at 801 US Highway 1, North Palm Beach, Florida 33408. We do not own any properties or land.
We believe our facilities are adequate and suitable for our current needs and that suitable additional or alternative space will be available if the need arises in the future.
Item 2 of the 10-K filed Dec 5, 2025.4
Leadership
Who has led SRX Global Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
20202025
- Chief executive officerKent Douglas Cunningham Apr 3, 2026 to now13
- Chief executive officerLionel F. Conacher Nov 4, 2022 to Sep 7, 202314
- ChairAdesh Anil Vora May 7, 2025 to now15
- ChairMichael S. Morrow Dec 28, 2015 to Dec 28, 201516
- PresidentDavender Sohi May 7, 2025 to now17
- PresidentDavid Richard Lelong Feb 5, 2016 to Feb 5, 201618
- PresidentMichael S. Morrow Dec 28, 2015 to Dec 28, 201516
- Chief financial officerSharla A. Cook Jul 8, 2021 to Jan 13, 202319
- Chief operating officerRobert Sauermann Jun 16, 2022 to Jan 13, 202320
Board members and other officers (9)
- EVP, StrategyRobert Sauermann May 17, 2022 to Jun 1, 202221
- Board memberSimon Alexander Malcolm Conway May 7, 2025 to now22
- Board memberGil Fronzaglia Jul 8, 2021 to Feb 5, 202423
- Board memberJeff D. Davis Jul 8, 2021 to Jul 12, 202124
- Board memberJohn M. Word Iii. Jul 8, 2021 to Feb 5, 202425
- Board memberLori Taylor Jul 8, 2021 to Jul 12, 202126
- Board memberLionel F. Conacher Oct 8, 2021 to now27
- Board memberArlene Dickinson Oct 15, 2021 to Feb 5, 202428
- Board memberDavid Richard Lelong Feb 5, 2016 to Feb 5, 201618
Named in SEC Form D filings
People the company listed in its private-offering notices.
Former names
Timeline
- Oct 7, 20268-K Entered a material agreement30
- Oct 6, 20268-K Regulation FD disclosure31
- Sep 9, 20268-K Entered a material agreement32
- Sep 2, 20268-K Entered a material agreement33
- Aug 28, 20268-K Entered a material agreement; Unregistered sale of shares34
- Aug 19, 20268-K Results of operations35
- Jul 29, 20268-K Unregistered sale of shares36
- Jul 28, 20268-K Unregistered sale of shares37
- Jul 21, 20268-K Entered a material agreement38
- Jul 16, 20268-K Listing notice or transfer39
- Jul 15, 20268-K Regulation FD disclosure40
- Jul 10, 20268-K Regulation FD disclosure41
- Apr 3, 2026New chief executive Kent Douglas Cunningham becomes CEO13
- Nov 4, 2022New chief executive Lionel F. Conacher becomes CEO14
Calendar
When it reported results
- Aug 19, 2026Reported quarterly or annual results35
- Mar 31, 2025Reported quarterly or annual results42
- Nov 15, 2024Reported quarterly or annual results43
- Aug 26, 2024Reported quarterly or annual results44
- May 21, 2024Reported quarterly or annual results45
- Apr 17, 2024Reported quarterly or annual results46
- Nov 14, 2023Reported quarterly or annual results47
- Aug 22, 2023Reported quarterly or annual results48
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
285 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 98 major events, 70 insider forms, 20 large holders, 1 private raises, 75 other. The latest 20:
- Oct 7, 20268-K EDGAR
- Oct 6, 20268-K EDGAR
- Sep 9, 20268-K EDGAR
- Sep 2, 20268-K EDGAR
- Aug 28, 20268-K EDGAR
- Aug 19, 20268-K EDGAR
- Aug 13, 202610-Q EDGAR
- Jul 29, 20268-K/A EDGAR
- Jul 28, 20268-K EDGAR
- Jul 21, 20268-K EDGAR
- Jul 16, 2026424B3 EDGAR
- Jul 16, 2026424B3 EDGAR
- Jul 16, 20268-K EDGAR
- Jul 15, 20268-K EDGAR
- Jul 10, 20268-K EDGAR
- Jul 8, 2026SCHEDULE 13G/A EDGAR
- Jul 6, 2026S-8 EDGAR
- Jun 26, 20268-K EDGAR
- Jun 25, 2026SCHEDULE 13G EDGAR
- Jun 24, 20268-K EDGAR
The 285 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
37 open-market trades by officers, directors and large owners since October 2021: 36 buys and 1 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 23, 2024 | Conacher Lionel F.Director | Sale | 635 | $1.71 | $1.1K | Form 4 |
| Nov 20, 2024 | Conacher Lionel F.Director | Buy | 5,000 | $1.71 | $8.6K | Form 4 |
| Feb 1, 2024 | Conacher Lionel F.Director | Buy | 8,418 | $11.88 | $100.0K | Form 4 |
| Sep 7, 2023 | Young MichaelDirector | Buy | 20,000 | $0.13 | $2.6K | Form 4 |
| Sep 7, 2023 | Young MichaelDirector | Buy | 20,000 | $0.13 | $2.6K | Form 4 |
| Sep 5, 2023 | Conacher Lionel F.Director | Buy | 17,045 | $6.97 | $118.8K | Form 4 |
| Sep 7, 2022 | Young DonaldChief Sales Officer | Buy | 11,000 | $1.50 | $16.5K | Form 4 |
| Sep 2, 2022 | Sauermann RobertCOO | Buy | 1,750 | $1.70 | $3.0K | Form 4 |
| Aug 30, 2022 | Sauermann RobertCOO | Buy | 1,750 | $1.82 | $3.2K | Form 4 |
| Aug 29, 2022 | Young DonaldChief Sales Officer | Buy | 11,000 | $1.76 | $19.4K | Form 4 |
| Aug 15, 2022 | Sauermann RobertCOO | Buy | 2,000 | $1.98 | $4.0K | Form 4 |
| Jun 15, 2022 | Sauermann RobertCOO | Buy | 1,000 | $2.40 | $2.4K | Form 4 |
| Jun 1, 2022 | Sauermann RobertCOO | Buy | 500 | $2.39 | $1.2K | Form 4 |
| May 27, 2022 | Young MichaelDirector | Buy | 2,500 | $2.68 | $6.7K | Form 4 |
| May 27, 2022 | Young MichaelDirector | Buy | 0 | Form 4 | ||
| May 26, 2022 | Young MichaelDirector | Buy | 1,000 | $2.47 | $2.5K | Form 4 |
| May 25, 2022 | Young MichaelDirector | Buy | 5,500 | $2.48 | $13.6K | Form 4 |
| May 20, 2022 | Young MichaelDirector | Buy | 500 | $2.40 | $1.2K | Form 4 |
| May 19, 2022 | Young MichaelDirector | Buy | 452 | $2.14 | $967 | Form 4 |
| May 17, 2022 | Young MichaelDirector | Buy | 22,800 | $2.16 | $49.1K | Form 4 |
All 37 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Les Filles, LLCSCHEDULE 13G/A, 2 filings Jun 25, 2026 to Jul 8, 202649
- Kevin EganSCHEDULE 13G, 1 filing Feb 12, 202650
- Altium Capital Management LLCSCHEDULE 13G/A, 4 filings Aug 9, 2024 to May 15, 202551
- HEP Partners LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202452
- Edward James Brown Jr.SC 13G/A, 2 filings Feb 28, 2022 to Feb 14, 202353
- John M. Word Iii.SC 13G/A, 2 filings Feb 11, 2022 to Feb 14, 202354
- Brandywine Global Investment Management, LLCSC 13G/A, 2 filings Feb 10, 2022 to Feb 13, 202355
- Cavalry Fund I LPSC 13G/A, 2 filings Feb 4, 2022 to Feb 13, 202356
- Must Asset Management Inc.SC 13G/A, 3 filings Nov 4, 2021 to Feb 7, 202357
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2023 | Kent Cunningham | 52 | $350.0K | $775.0K58 |
| 2023 | Donald Young | $275.0K | $332.7K58 | |
| 2023 | Carolina Martinez | $240.0K | $330.3K58 | |
| 2023 | Sharla A. Cook | $250.0K | $281.2K58 | |
| 2023 | Robert Sauermann | $240.0K | $269.8K58 | |
| 2023 | Lionel F. Conacher | 60 | $160.0K | $173.3K58 |
| 2022 | Chief Sales Officer | $275.0K | $886.6K58 | |
| 2022 | Executive Vice PresidentStrategy | $240.0K | $713.7K58 | |
| 2022 | Chief Financial Officer | $250.0K | $513.4K58 | |
| 2022 | Interim ChiefExecutive Officer | $160.0K | $331.9K58 | |
| 2021 | Chief Sales Officer | $250.0K | $1.3M58 | |
| 2021 | Executive Vice PresidentStrategy | $225.0K | $861.2K58 | |
| 2021 | Chief Financial Officer | $200.0K | $562.0K58 |
Money raised
Private offerings the company reported to the SEC on Form D.
- Oct 31, 2025Raised $15.2 million in a private offering of equity Form D: $30.5 million offered in all Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| SBI Securities Co., Ltd. | 56,584 | $5.1K | 0.0% | New |
| Bogart Wealth, LLC | 10,000 | $907 | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How SRX Global Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARSRX Global Inc.1
- CIK0001471727
- Employer ID (EIN)83-42845574
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
- Incorporated inDelaware4
- Fiscal year endsSeptember 301
- Industry code (SIC)2080 Beverages1
- SEC reviewing officeOffice of Manufacturing, Division of Corporation Finance1
- Business address801 Us Highway 1, North Palm Beach, FL 334081
- Phone813-792-43521
- Shares outstanding20,265,391 as of Aug 13, 202612
- Public float$9.1M as of Mar 31, 20254
- AuditorDAVIDSON & COMPANY LLP, Vancouver, Canada PCAOB ID 731; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceSep 16, 20091
- Filings564 in all: 8-K (191), 4 (79), 10-Q (50), CORRESP (23), 424B3 (21), 3 (18), 10-K (16), D (16)1
All 49 form types
S-1/A (14), NT 10-Q (13), UPLOAD (11), SC 13G/A (10), EFFECT (9), 8-K/A (8), NT 10-K (7), S-1 (7), SC 13G (7), PRE 14C (6), DEF 14A (5), SC 13D (5), DEF 14C (4), S-8 (4), 3/A (3), DEFA14A (3), SCHEDULE 13G/A (3), 10-K/A (2), 4/A (2), D/A (2), PRE 14A (2), PRER14C (2), RW (2), SCHEDULE 13G (2), 1-A (1), 10-KT (1), 10-Q/A (1), 144 (1), 424B1 (1), 424B4 (1), 8-A12B (1), CERT (1), DEFR14C (1), NT 10-Q/A (1), POS AM (1), PREM14A (1), S-1MEF (1), S-3 (1), S-4 (1), S-4/A (1), SEC STAFF ACTION (1)
- Latest filingsAnnual report (10-K) Dec 5, 2025
Quarterly report (10-Q) Aug 13, 2026
Proxy statement (DEF 14A) Jan 28, 2025
Latest 8-K (8-K) Oct 7, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.001 par value share | SRXH | NYSE American |
From the cover page of the 10-K filed Dec 5, 2025 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks SRX Global Inc. names in Item 1A of its 10-K filed Dec 5, 2025: 74 risks under these headings, as written.4
- General Risks
- We have incurred significant losses in prior periods, and losses in the future could cause the quoted price of the Company’s common stock to decline or have a material adverse effect on the Company’s financial condition, the Company’s ability to pay its debts as they become due, and on its cash flows.
- If we are unable to manage future expansion effectively, our business may be adversely impacted.
- The Company’s ability to be successful will depend upon the efforts of the Company’s Board and our key personnel and the loss of such persons could negatively impact the operations and profitability of the Company’s business.
- If we are unable to recruit and retain key personnel, our business may be harmed.
- Our business plan is not based on independent market studies.
- Our Board of Directors may change our policies without shareholder approval.
- We need to obtain financing in order to continue our operations and pursue strategic transactions.
- We currently do not have sufficient cash to fully implement our business plan.
- The Company’s business and operations could be negatively affected if it becomes subject to any securities litigation or shareholder activism, which could cause the Company to incur significant expense, hinder execution of business and growth strategy and impact its stock price.
- Risks Related to the Company’s Specialty Pharmacy Business
- SRx Health conducts its business in a highly regulated industry and environment.
The other 64 risks
- Changes in reimbursement programs, prescription drug pricing and commercial terms could adversely affect SRx Health’s operations and financial performance.
- Inflation risk
- SRx Health’s business is highly competitive and SRx Health may not be able to compete successfully against current and future competitors.
- SRx Health’s business is impacted by the interplay between brand name and generic drugs
- Changes in drug development and prescription mix may impact SRx Health’s results of operation
- Product liability, product recall or personal injury issues could damage SRx Health’s reputation and have a significant adverse effect on SRx Health’s business, operating results, cash flows and/or financial condition.
- The drug products that SRx Health carries have a set shelf life
- Continued operation of SRx Health’s distribution facilities is critical to SRx Health’s operations
- Conducting clinical trials involve a high degree of risk
- There may be delays or stoppages in SRx Health’s clinical trials due to circumstances beyond SRx Health’s control
- Negative results from clinical trials or studies of others and adverse safety events involving the targets of SRx Health’s products may have an adverse impact on SRx Health’s future commercialization efforts.
- SRx Health’s insurance policies may not be sufficient to cover all claims
- SRx Health is subject to a variety of business continuity hazards and risks, any of which could interrupt SRx Health’s operations or otherwise adversely affect its performance and operating results.
- SRx Health’s risk management policies and procedures may not be fully effective in mitigating SRx Health’s risk exposure in all market environments or against all types of risks, which could expose SRx Health to losses and liability and otherwise harm SRx Health’s business.
- Consumer opinion of SRx Health may be impacted in case of reputational damages to SRx Health’s suppliers
- Healthcare professional errors may harm SRx Health’s business and reputation
- Consolidation in the supply chain may negatively impact drug prices and SRx Health’s ability to compete
- SRx Health relies on third-party suppliers for a significant portion of its supply of products
- SRx Health’s quarterly results of operations may fluctuate and, as a result, SRx Health may fail to meet or exceed the expectations of investors or securities analysts which could cause SRx Health’s share price to decline.
- Change in tax and trade policies, tariffs and other government regulations affecting trade between Canada and other countries could adversely affect SRx Health.
- Disruption of the global supply chain and ineffective service providers could adversely impact SRx Health’s business
- Failure to meet customer expectations may harm SRx Health’s brand and reputation, its ability to retain and grow its customer base and its operating results.
- If SRx Health cannot keep pace with rapid developments in healthcare technology and change in SRx Health’s industry and continue to grow its patient base, the use of SRx Health’s services could decline, reducing SRx Health’s revenue.
- SRx Health’s use and disclosure of personally identifiable information, including personal health information, is subject to privacy and security regulations.
- SRx Health relies on the relationships that SRx Health has established with major drug manufacturers and specialty practitioners to conduct SRx Health’s business, and changes to these relationships may impair SRx Health’s operations.
- SRx Health may be subject to information technology systems impairment and cyber-attacks in the future
- SRx Health’s services must integrate and interoperate with a variety of operating systems, software, hardware, web browsers and networks.
- Failure to properly manage inventories and anticipate demand may impact SRx Health’s financial performance
- Reliance on data obtained from third party sources
- Change in population demographics could have an adverse effect on SRx Health’s business, operations, financial condition and results of operations.
- If SRx Health is unable to hire, retain and motivate qualified personnel, its business will suffer
- From time to time, SRx Health may become defendants in legal proceedings as to which SRx Health is unable to assess its exposure, and which could become significant liabilities in the event of an adverse judgment.
- Labor-related matters, including labor disputes, may adversely affect SRx Health’s operations
- Goodwill and other intangible assets could, in the future, become impaired
- Conflicts of interest may arise between SRx Health and its directors and officers as a result of other business activities undertaken by such individuals.
- SRx Health is subject to risks associated with leasing space and equipment and is subject to a number of long-term non-cancelable leases with substantial lease payments.
- SRx Health may be unable to adequately protect its proprietary and intellectual property rights
- Being accused of infringing intellectual property rights of others
- SRx Health may become involved in regulatory or agency proceedings, investigations and audits
- The impact of economic conditions, including the resulting effect on spending by consumers, may adversely affect SRx Health’s business, operating results and financial condition.
- Risks Relating to the SRx Health’s Growth Strategy
- SRx Health may not be able to successfully implement SRx Health’s growth strategy.
- A portion of SRx Health’s growth depends on SRx Health’s ability to complete future acquisitions, and failure to do so in a timely manner, or on less favorable terms to SRx Health, could impede SRx Health’s ability to execute portions of SRx Health’s business strategy
- Any future acquisitions, partnerships or joint ventures that SRx Health makes or enters into could disrupt SRx Health’s business and harm SRx Health’s financial condition.
- Competition for acquisition candidates, consolidation within the pharmacy industry and economic and market conditions may limit SRx Health’s ability to grow through acquisitions.
- Changes in the Canadian healthcare industry and regulatory environment could negatively affect SRx Health’s growth and financial projections.
- Risks Related to the Company’s Pet Health and Wellness Business
- Increases in sourcing, manufacturing, freight and/or warehousing costs, supply shortages, interruption in Halo’s sourcing operations and/or supply changes could have an adverse effect on Halo’s business, financial condition, and operating results.
- If Halo fails to maintain and expand Halo’s brand, or the quality of Halo’s products that customers have come to expect, Halo’s business could suffer.
- Halo may not be able to successfully implement and/or manage Halo’s growth strategy on a timely basis or Halo may not grow at all.
- If Halo does not successfully develop additional products and services, or if such products and services are developed but not successfully commercialized, Halo’s business will be adversely affected.
- Because Halo is engaged in a highly competitive business, if Halo is unable to compete effectively, Halo’s results of operations could be adversely affected.
- If Halo fails to attract new customers, or retain existing customers, or fail to do either in a cost-effective manner, Halo may not be able to increase sales.
- Food safety and food-borne illness incidents may materially adversely affect Halo’s business by exposing Halo to lawsuits, product recalls or regulatory enforcement actions, increasing Halo’s operating costs and reducing demand for Halo’s product offerings.
- Halo may not be able to manage Halo’s manufacturing and supply chain effectively, which may adversely affect Halo’s results of operations.
- If any of Halo’s independent shipping providers experience delays or disruptions, Halo’s business could be adversely affected.
- Halo’s intellectual property rights may be inadequate to protect Halo’s business.
- Halo depends on the knowledge and skills of Halo’s senior management and other key employees, and if Halo is unable to retain and motivate them or recruit additional qualified personnel, Halo’s business may suffer.
- A failure of one or more key information technology systems, networks or processes may materially adversely affect Halo’s ability to conduct Halo’s business.
- Halo relies heavily on third-party commerce platforms to conduct Halo’s businesses. If one of those platforms is compromised, Halo’s business, financial condition and results of operations could be harmed.
- Halo may face difficulties as Halo expands business and operations into jurisdictions in which Halo has no prior operating experience.
- There may be decreased spending on pets in a challenging economic climate.
- Significant merchandise returns or refunds could harm Halo’s business.
- Halo may seek to grow Halo’s company and business through acquisitions, investments or through strategic alliances and Halo’s failure to identify and successfully integrate and manage these assets could have a material adverse effect on the anticipated benefits of the acquisition and Halo’s business, financial condition or results of operations.
- Premiums for Halo’s insurance coverage may not continue to be commercially justifiable, and Halo’s insurance coverage may have limitations and other exclusions and may not be sufficient to cover Halo’s potential liabilities.
- Adverse litigation judgments or settlements resulting from legal proceedings relating to Halo’s business operations could materially adversely affect Halo’s business, financial condition and results of operations.
- If third parties claim that Halo infringes upon their intellectual property rights, Halo’s business and results of operations could be adversely affected.
- Failure to comply with the U.S. Foreign Corrupt Practices Act, other applicable anti-corruption and anti-bribery laws, and applicable trade control laws could subject Halo to penalties and other adverse consequences.
Legal proceedings
From time to time, we are subject to litigation and other proceedings that arise in the ordinary course of our business. Subject to the inherent uncertainties of litigation and although no assurances are possible, we believe that there are no pending lawsuits or claims that, individually or in the aggregate, will have a material adverse effect on our business, financial condition or our yearly results of operations.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARSRX Global Inc. filings on SEC EDGAR
- 2SEC EDGARSRX Global Inc. 10-K for fiscal 2025
- 3SEC EDGARSRX Global Inc. filings on SEC EDGAR
- 4
- 5SEC EDGARSRX Global Inc. 10-K for fiscal 2018
- 6SEC EDGARSRX Global Inc. 10-K for fiscal 2019
- 7SEC EDGARSRX Global Inc. 10-K for fiscal 2020
- 8SEC EDGARSRX Global Inc. 10-K for fiscal 2021
- 9SEC EDGARSRX Global Inc. 10-K for fiscal 2022
- 10SEC EDGARSRX Global Inc. 10-K for fiscal 2023
- 11SEC EDGARSRX Global Inc. 10-Q for fiscal 2026
- 12SEC EDGARSRX Global Inc. 10-Q for fiscal 2026
- 13
- 14
- 15SEC EDGARAdesh Anil Vora, Chair
- 16SEC EDGARMichael S. Morrow, Chair
- 17SEC EDGARDavender Sohi, President
- 18SEC EDGARDavid Richard Lelong, President
- 19
- 20
- 21SEC EDGARRobert Sauermann, EVP, Strategy
- 22
- 23SEC EDGARGil Fronzaglia, Board member
- 24SEC EDGARJeff D. Davis, Board member
- 25SEC EDGARJohn M. Word Iii., Board member
- 26SEC EDGARLori Taylor, Board member
- 27SEC EDGARLionel F. Conacher, Board member
- 28SEC EDGARArlene Dickinson, Board member
- 29
- 30SEC EDGAREntered a material agreement
- 31SEC EDGARRegulation FD disclosure
- 32SEC EDGAREntered a material agreement
- 33SEC EDGAREntered a material agreement
- 34
- 35SEC EDGARResults of operations
- 36SEC EDGARUnregistered sale of shares
- 37SEC EDGARUnregistered sale of shares
- 38SEC EDGAREntered a material agreement
- 39SEC EDGARListing notice or transfer
- 40SEC EDGARRegulation FD disclosure
- 41SEC EDGARRegulation FD disclosure
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58